A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Smoldering Multiple Myeloma Clinical Trial

Official title:

A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION) Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04920084
• Other study ID #: 21-135
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 3, 2021
• Est. completion date: June 2025

Study information

• Verified date: March 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will test whether a plant-based diet is practical (feasible) for overweight people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The researchers will decide how practical the diet is by looking at how much weight participants lose and how well they are able to stick to the diet. The researchers will also determine whether the diet is effective in preventing multiple myeloma in participants. In addition, they will look at how safe the plant-based diet is for participants, and see if the diet affects participants' quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 23
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• BMI =25

• Confirmed diagnosis of MGUS or SMM

• M spike (immunoglobulin) =0.2 g/dL or abnormal free light chain ratio with increased level of the appropriate involved light chain

• Secretory disease

• Age =18 years

• Willingness to comply with all study-related procedures

• ECOG performance status of 0-3

• Interest to learn to cook plant based recipes

Exclusion Criteria:

• Patients that already follow a whole foods plant based or vegan diet (ovo-lactovegetarian diets are not excluded)

• Legume allergy

• Severe allergies, such as anaphylactic shock to peanuts

• Concurrent participation in weight loss/dietary/exercise programs

• Mental impairment leading to inability to cooperate

• Enrollment onto any other therapeutic investigational study

• Concurrent pregnancy

• Patients with a known diagnosis of diabetes mellitus will not be excluded but will need to be followed regularly with an endocrinologist/primary care physician during the trial period.

• Positive HBV, HCV, HIV PCR testing

• Non English speaking

• = Grade 2 electrolyte abnormalities as defined by CTCAEv5.0 (need to be resolved before enrolling on study)

• If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely

Related Conditions & MeSH terms

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Paraproteinemias
• Smoldering Multiple Myeloma

Intervention

Other:
• Plant based meals
For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack	Commack	New York
United States	Memorial Sloan Kettering Westchester	Harrison	New York
United States	Memorial Sloan Kettering Monmouth	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Nassau	Uniondale	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight loss- body mass index (BMI) reduction	Weight loss is defined as the average decrease in BMI at 12 weeks	12 weeks
Primary	Patient adherence to the diet	Intervention defined as =70% of participants consuming a WFPBD for =70% of meals of the 12-week intervention period (determined via a dietary recall and nutritional survey).	12 weeks

External Links

•   Memorial Sloan Kettering Cancer Center